Ralph J. Hauke
YOU?
Author Swipe
View article: Sequencing of Radium-223 and Lutetium-177 Vipivotide Tetraxetan: Maximizing the Benefit of Systemic Targeted Radiation Therapy in Metastatic Castration-Resistant Prostate Cancer
Sequencing of Radium-223 and Lutetium-177 Vipivotide Tetraxetan: Maximizing the Benefit of Systemic Targeted Radiation Therapy in Metastatic Castration-Resistant Prostate Cancer Open
As the majority of men with metastatic castration-resistant prostate cancer first present with bone-only metastases, they may be treated initially with radium-223, while still remaining eligible to benefit from chemotherapy and 177
View article: 44Overview of tivozanib (tivo) safety in phase 3 clinical trials in patients with metastatic renal cell carcinoma (mRCC)
44Overview of tivozanib (tivo) safety in phase 3 clinical trials in patients with metastatic renal cell carcinoma (mRCC) Open
Background Tivo is a potent and highly selective VEGFR inhibitor designed to optimize VEGF blockade and minimize off-target toxicities. In TiNivo-2, patients with mRCC who had previous exposure to ICI, were randomized to receive study trea…
View article: Supplementary Table S2 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Table S2 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
COXPH model for patients with at least 6-mo overall survival
View article: Supplementary Figure S5 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Figure S5 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Copy number alterations (CNAs) and fusions among cohort
View article: Supplementary Fiugre S4 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Fiugre S4 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Overall survival by RUCA code and poverty
View article: Supplementary Figure S2 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Figure S2 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Overall survival of cohort by stage
View article: Supplementary Figure S3 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Figure S3 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Overall survival by RUCA code and poverty
View article: Supplementary Table S1 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Table S1 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Description of rural-urban commuting area (RUCA) codes
View article: Supplementary Figure S6 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Figure S6 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Prevalence of common mutations in tumor subtypes
View article: Supplementary Figure S8 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Figure S8 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Comparison of overall survival among chemotherapy-treated TP53-mutated and TP53-wild type patients in Caris CODEai clinico-genomic database
View article: Supplementary Table S3 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Table S3 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
COXPH model for patients with stage information
View article: Supplementary Figure S1 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Figure S1 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Comparison of Caris cohort data with Puckrein dataset
View article: Supplementary Figure S7 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Figure S7 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Gene mutations according to poverty level and RUCA codes
View article: COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts
COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts Open
PURPOSE The COSMIC-021 study assessed the safety and efficacy of cabozantinib plus atezolizumab in advanced solid tumors. Presented here are results from the expansion cohorts with advanced urothelial carcinoma (UC). METHODS This phase Ib …
View article: Supplementary Figure S7 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Figure S7 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Gene mutations according to poverty level and RUCA codes
View article: Supplementary Figure S6 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Figure S6 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Prevalence of common mutations in tumor subtypes
View article: Supplementary Figure S8 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Figure S8 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Comparison of overall survival among chemotherapy-treated TP53-mutated and TP53-wild type patients in Caris CODEai clinico-genomic database
View article: Supplementary Figure S5 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Figure S5 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Copy number alterations (CNAs) and fusions among cohort
View article: Supplementary Table S1 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Table S1 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Description of rural-urban commuting area (RUCA) codes
View article: Supplementary Figure S2 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Figure S2 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Overall survival of cohort by stage
View article: Supplementary Table S2 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Table S2 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
COXPH model for patients with at least 6-mo overall survival
View article: Data from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Data from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Health disparities present a barrier to successful oncology treatment. The potential for precision oncology to reduce health disparities has not previously been analyzed. We performed a retrospective analysis of 12,627 patients from six ma…
View article: Supplementary Figure S3 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Figure S3 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Overall survival by RUCA code and poverty
View article: Supplementary Table S3 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Table S3 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
COXPH model for patients with stage information
View article: Supplementary Fiugre S4 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Fiugre S4 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Overall survival by RUCA code and poverty
View article: Supplementary Figure S1 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Supplementary Figure S1 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Comparison of Caris cohort data with Puckrein dataset
View article: Figure 3 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Figure 3 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Gene mutations by race. A, Percentage of tumors from Black versus White patients that are positive for the indicated gene mutations. #, P < 0.001; ns, not significant. B–E, Probability of Black patients having a…
View article: Figure 2 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Figure 2 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Genomic features and clinico-demographic associations of cohort. A, Total number of tumors positive for each mutated gene. B, Percentage of total tumors from each study site for the top 20 most commonly mutated genes. C,
View article: Figure 1 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Figure 1 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
Tumor lineages of the cohort and analysis of OS by race. A, Total numbers of each tumor type broken down by study site. B, Percentage of the total made up by each study site for the top 10 most represented tumor types. C,<…
View article: Table 2 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Table 2 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy Open
COXPH model for all patients in the cohort